Allakos Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Feb 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 3, 2027The maintenance fee for Anti-Siglec-7 antibodies for the treatment of cancer (US 11,773,162) comes due Apr 3, 2027. Unpaid by Oct 4, 2027, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Anti-Siglec-7 antibodies having reduced effector function (US 11,912,766) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 1 fee due Sep 30, 2027The maintenance fee for Methods and compositions for treating systemic mastocytosis (US 10,604,577) comes due Sep 30, 2027. Unpaid by Mar 31, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,546,215 | Anti-Siglec-8 antibodies and methods of use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,183,996 | Methods and Compositions for Treating SIGLEC-8 Associated Diseases In force · High confidence | In force | High confidence | |
| US 10,774,145 | Methods and compositions for treating fibrotic diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 10,604,577 | Methods and compositions for treating systemic mastocytosis In force · From the USPTO record | In force | From the USPTO record | |
| US 11,203,638 | Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis In force · From the USPTO record | In force | From the USPTO record | |
| US 11,912,766 | Anti-Siglec-7 antibodies having reduced effector function In force · From the USPTO record | In force | From the USPTO record | |
| US 11,773,162 | Anti-Siglec-7 antibodies for the treatment of cancer In force · From the USPTO record | In force | From the USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 3 abandoned · 14 no status recorded